Revumenib: the newly approved food drug administration drug for the treatment of relapsed acute leukemia with a KMT2A translocation
DOI:
https://doi.org/10.18203/2320-6012.ijrms20250291Keywords:
Revumenib, US food and drug administration, Acute leukemiaAbstract
On November 15, 2024, the US food and drug administration (FDA) granted approval for Revumenib for the treatment of relapsed or refractory acute leukemia in adult patients and pediatric patients aged 12 months or older who exhibit a lysine methyltransferase 2A (KMT2A) translocation. This subset of acute leukemia is driven by the pathological interaction between menin proteins and the KMT2A gene, a critical epigenetic regulator. This interaction facilitates the rearrangement of KMT2A, which underpins leukemogenesis, contributing to the pathophysiology in approximately 10% of acute leukemia cases.
Metrics
References
Garber A, Klein E, Bruce S, Sankoh S, Mohideen P. Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2006;8(2):156-63. DOI: https://doi.org/10.1111/j.1463-1326.2005.00570.x
Issa GC, Aldoss I, DiPersio J, Cuglievan B, Stone R, Arellano M, et al. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature. 2023;615(7954):920-4. DOI: https://doi.org/10.1038/s41586-023-05812-3
Issa GC, Aldoss I, Thirman MJ, DiPersio J, Arellano M, Blachly JS, et al. Menin Inhibition with Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101). J Clin Oncol. 2024;JCO2400826. DOI: https://doi.org/10.1200/JCO.24.00826
Hussain H, Zaidi SMF, Hasan SM, Jahan AS, Rangwala BS, Rangwala HS, et al. Revumenib (SNDX-5613): a promising menin inhibitor for the management of relapsed and refractory acute myeloid leukaemia (AML). Ann Med Surg (Lond). 2024;86(5):2379-81. DOI: https://doi.org/10.1097/MS9.0000000000001888
Sanz MA, Montesinos P. How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia. Blood. 2014;123(18):2777-82. DOI: https://doi.org/10.1182/blood-2013-10-512640
Downloads
Published
How to Cite
Issue
Section
